# KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma

> **NCT04469725** · PHASE2 · TERMINATED · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 95 (actual)

## Conditions studied

- Thymic Carcinoma

## Interventions

- **DRUG:** KN046

## Key facts

- **NCT ID:** NCT04469725
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-02
- **Primary completion:** 2023-07-07
- **Final completion:** 2023-07-07
- **Target enrollment:** 95 (ACTUAL)
- **Why stopped:** The termination of this study does not involve safety issues. The overall safety of KN046 is good, and no new safety signals have been found. The decision to terminate this study was made due to the adjustment of the sponsor's development strategy.
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04469725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04469725, "KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04469725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*